What is the primary objective of DORA?

The primary objective of DORA is to strengthen the digital operational resilience of the EU financial sector against ICT disruptions, including cyberattacks, system failures, and third-party risks. Regulation (EU) 2022/2554 mandates proactive ICT risk management, incident reporting, resilience testing, and third-party oversight for 20 types of financial entities and critical ICT third-party providers (CTPPs), applicable since January 17, 2025.

Who is legally or professionally required to comply with DORA?

DORA legally requires compliance from approximately 22,000 EU-regulated financial entities across 20 types, including credit institutions, insurance undertakings, investment firms, payment institutions, and crypto-asset service providers, plus critical ICT third-party providers (CTPPs). CTPPs, such as cloud and data analytics firms designated by ESAs, face direct oversight, with ~1,000+ EU ICT providers in scope.

Does DORA require an external audit or third-party certification?

DORA does not mandate external audits or third-party certification but requires independent execution of digital operational resilience testing, including risk-based annual basic tests and triennial threat-led penetration testing (TLPT) for critical entities. Results must be reported to authorities, with ESAs validating TLPT scope via Regulatory Technical Standards (RTS) published July 17, 2024.

How often should an assessment for DORA be performed?

DORA mandates annual basic ICT resilience tests, such as vulnerability assessments, and triennial advanced threat-led penetration testing (TLPT) for designated critical or important entities. ICT risk management frameworks require annual reviews, with proportionality applied based on entity size, complexity, and risk exposure.

What are the consequences of non-compliance with DORA?

Non-compliance with DORA incurs administrative penalties and remedial measures determined by Member States, while ESAs can impose periodic penalty payments on CTPPs up to 1% of their average daily worldwide turnover. Additional penalties include oversight fees up to €1 million annually for CTPPs and potential remediation orders.

An DORA be mapped to other international frameworks?

Yes, DORA's ICT risk management, incident reporting, testing, and third-party oversight provisions can be mapped to other international frameworks, leveraging its harmonized EU standards as a baseline. Financial entities often align existing programs, such as those for insurers under Solvency II, with DORA's RTS on ICT frameworks and TLPT.

What is the first step to begin implementing DORA?

The first step to implement DORA is conducting a gap analysis against the ICT risk management framework RTS published January 17, 2024, to identify deficiencies in ICT strategies, incident classification, and third-party policies. Prioritize mapping dependencies on CTPPs and establishing management body oversight to maintain compliance with the requirements enforced since January 17, 2025.

What is the primary objective of GMP?

GMP establishes minimum standards for manufacturing controls to ensure products are consistently produced and controlled to meet predefined quality criteria. It prevents contamination, mix-ups, mislabeling, and process variability through preventive systems like validated processes, independent quality oversight, and the "5 Ps" (People, Products, Procedures, Processes, Premises), rather than relying solely on final testing.

Who is legally or professionally required to comply with GMP?

GMP compliance is legally required for manufacturers of pharmaceuticals, biologics, APIs, and related products under FDA 21 CFR Parts 210/211, EU EudraLex Volume 4, and WHO GMP. This includes drug product firms, API producers (ICH Q7), contract manufacturers, and suppliers; medical devices follow aligned systems like 21 CFR Part 820.

Does GMP require an external audit or third-party certification?

GMP does not mandate third-party certification but requires regular regulatory inspections by authorities like FDA or EMA. Organizations must conduct internal audits/self-inspections and supplier audits; PIC/S and MRAs enable mutual recognition, but compliance is verified through unannounced official inspections and enforcement actions.

How often should an assessment for GMP be performed?

GMP assessments, including internal audits and self-inspections, must be conducted at planned intervals based on risk, typically annually with more frequent reviews for high-risk areas. Regulators expect ongoing monitoring via CAPA, change control, and Product Quality Reviews (e.g., annual per 21 CFR §211.180(e)); requalification follows maintenance or changes.

What are the consequences of non-compliance with GMP?

Non-compliance with GMP triggers regulatory actions including Form 483 observations, Warning Letters, import alerts, product seizures, civil money penalties (FDA), and consent decrees. Severe cases lead to recalls, market exclusion, criminal prosecution, and multimillion-dollar remediation costs, as seen in historical enforcement.

An GMP be mapped to other international frameworks?

Yes, GMP aligns closely with ICH Q7 (APIs), ICH Q9 (QRM), ICH Q10 (PQS), PIC/S, and WHO guidance for global harmonization. Core elements like quality systems, validation, and documentation map directly, enabling mutual recognition via MRAs while accommodating regional differences like EU QP certification.

What is the first step to begin implementing GMP?

The first step is conducting a comprehensive gap analysis against applicable regulations (e.g., 21 CFR 211, EU GMP) to identify deficiencies in the 5 Ps and develop a Validation Master Plan. This risk-based assessment prioritizes remediation, informs resource allocation, and establishes a PQS roadmap.

Standards Comparison

DORA vs GMP

DORA

Mandatory

2023

EU regulation for digital operational resilience in financial sector

GMP

Mandatory

1963

Global standards for manufacturing quality and safety controls

Quick Verdict

DORA mandates digital resilience for EU finance against ICT risks via testing and oversight, while GMP enforces manufacturing quality for pharma through validation and controls. Firms adopt DORA for regulatory compliance, GMP for patient safety and market access.

Digital Operational Resilience

DORA

Regulation (EU) 2022/2554 Digital Operational Resilience Act

Cost

€€€€

Complexity

High

Implementation Time

18-24 months

Key Features

Mandates comprehensive ICT risk management frameworks overseen by management
Requires 4-hour initial reporting for major ICT incidents
Imposes triennial threat-led penetration testing for critical entities
Establishes ESAs oversight of critical third-party providers
Harmonizes resilience requirements across 20 financial entity types

Manufacturing Quality

GMP

Good Manufacturing Practices (GMP)

Cost

€€€

Complexity

Medium

Implementation Time

18-24 months

Key Features

Preventive controls over end-product testing
Quality Risk Management (QRM) proportionality
Independent quality unit oversight
Validated processes and equipment qualification
Comprehensive documentation and traceability

Detailed Analysis

A comprehensive look at the specific requirements, scope, and impact of each standard.

DORA Details

What It Is

Digital Operational Resilience Act (DORA), Regulation (EU) 2022/2554, is a transformative EU regulation enhancing ICT resilience for the financial sector. Enacted December 2022 and applicable since January 2025, it targets 20 financial entity types and critical ICT providers against disruptions like cyberattacks. Employs a risk-based, proportional approach for ICT risk identification, mitigation, and monitoring.

Key Components

**ICT Risk ManagementFrameworks with strategies, controls, annual reviews.
**Incident ReportingLog, classify, notify within 4/72 hours for major events.
**Resilience TestingAnnual vulnerability scans; triennial TLPT.
**Third-Party OversightDue diligence, contracts, ESAs supervision of CTPPs. Built on harmonization principles; compliance via authority enforcement, including periodic penalty payments for CTPPs up to 1% of average daily worldwide turnover.

Why Organizations Use It

Mandated compliance averts fines, bolsters resilience amid rising threats (74% ransomware hit). Enhances trust, systemic stability, cross-border operations; spurs cybersecurity innovation.

Implementation Overview

Gap analysis, framework build, tool deployment, testing rollout, vendor reviews. Scaled by size/complexity; EU financial entities mandatory. Authority audits, no certification.

GMP Details

What It Is

Good Manufacturing Practice (GMP) is a regulatory framework establishing minimum enforceable standards for manufacturing controls in pharmaceuticals, biologics, and related sectors. Its primary purpose is to ensure products are consistently produced to quality standards through preventive systems, not end-product testing alone. It adopts a risk-based approach via Quality Risk Management (QRM) across the product lifecycle.

Key Components

Core pillars: 5 Ps (People, Premises, Processes, Procedures, Products)
Elements include Pharmaceutical Quality System (PQS), validated processes, independent quality oversight, documentation, training, facilities/equipment controls, supplier management, CAPA, and audits
Built on ICH Q9/Q10, FDA 21 CFR 210/211, EU EudraLex Vol. 4, WHO GMP
Compliance via inspections, no central certification but enforceable regionally

Why Organizations Use It

Meets legal requirements, prevents recalls/liability
Enhances supply reliability, market access, operational efficiency
Builds patient safety, stakeholder trust, competitive edge

Implementation Overview

Phased: gap analysis, QMS design, validation (IQ/OQ/PQ), training, audits
Applies to pharma/biologics manufacturers globally; scales by size/risk
Involves internal audits, regulatory inspections (e.g., FDA, EMA)

Key Differences

Aspect	DORA	GMP
Scope	ICT risk management, resilience testing, third-party oversight	Manufacturing controls, quality systems, process validation
Industry	EU financial sector entities and critical ICT providers	Pharmaceuticals, biologics, medical devices globally
Nature	Mandatory EU regulation with ESAs enforcement	Enforceable regulatory standards (FDA, EU, WHO)
Testing	Annual basic tests, triennial TLPT for critical entities	Process/equipment validation (IQ/OQ/PQ), cleaning validation
Penalties	Up to 2% global turnover fines	Warning letters, recalls, import alerts, fines

Scope

DORA

ICT risk management, resilience testing, third-party oversight

GMP

Manufacturing controls, quality systems, process validation

Industry

DORA

EU financial sector entities and critical ICT providers

GMP

Pharmaceuticals, biologics, medical devices globally

Nature

DORA

Mandatory EU regulation with ESAs enforcement

GMP

Enforceable regulatory standards (FDA, EU, WHO)

Testing

DORA

Annual basic tests, triennial TLPT for critical entities

GMP

Process/equipment validation (IQ/OQ/PQ), cleaning validation

Penalties

DORA

Up to 2% global turnover fines

GMP

Warning letters, recalls, import alerts, fines

Frequently Asked Questions

Common questions about DORA and GMP

DORA FAQ

GMP FAQ

You Might also be Interested in These Articles...

CMMC Sustainment Mastery: Continuous Monitoring, Annual Affirmations, and Subcontractor Flow-Down Playbook

Master CMMC sustainment beyond certification: continuous monitoring dashboards, SPRS/eMASS affirmations, enforceable subcontractor clauses. Get templates for ve

SOC 2 Trust Services Criteria in Plain English: Side-by-Side Decoder with Real-World Analogies

Decode SOC 2 Trust Services Criteria (Security, Availability, Confidentiality, Processing Integrity, Privacy) into plain English with tables, TL;DRs & analogies

CMMC Level 2 Implementation Guide for Small DIB Contractors: First 5 Steps to C3PAO Certification with Infographic

Actionable CMMC Level 2 guide for small DIB contractors: 5-step roadmap to C3PAO certification with infographic on timelines, costs & POA&Ms. Achieve DoD compli

Run Maturity Assessments with GRADUM

Transform your compliance journey with our AI-powered assessment platform

Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.

100+ Standards & Regulations

AI-Powered Insights

Collaborative Assessments

Actionable Recommendations

Explore More Comparisons

See how DORA and GMP compare against other standards

Other DORA Comparisons

Other GMP Comparisons

What It Is

Key Components

**ICT Risk ManagementFrameworks with strategies, controls, annual reviews.

**Incident ReportingLog, classify, notify within 4/72 hours for major events.

**Resilience TestingAnnual vulnerability scans; triennial TLPT.

**Third-Party OversightDue diligence, contracts, ESAs supervision of CTPPs. Built on harmonization principles; compliance via authority enforcement, including periodic penalty payments for CTPPs up to 1% of average daily worldwide turnover.

What It Is

Key Components

Core pillars: 5 Ps (People, Premises, Processes, Procedures, Products)

Elements include Pharmaceutical Quality System (PQS), validated processes, independent quality oversight, documentation, training, facilities/equipment controls, supplier management, CAPA, and audits

Built on ICH Q9/Q10, FDA 21 CFR 210/211, EU EudraLex Vol. 4, WHO GMP

Compliance via inspections, no central certification but enforceable regionally

Aspect

DORA

GMP

Scope

ICT risk management, resilience testing, third-party oversight

Manufacturing controls, quality systems, process validation

Industry

EU financial sector entities and critical ICT providers

Pharmaceuticals, biologics, medical devices globally

Nature

Mandatory EU regulation with ESAs enforcement

Enforceable regulatory standards (FDA, EU, WHO)

Testing

Annual basic tests, triennial TLPT for critical entities

Process/equipment validation (IQ/OQ/PQ), cleaning validation

Penalties

Up to 2% global turnover fines

Warning letters, recalls, import alerts, fines